mr JOSHUA JORGENSEN

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs including the creation of a national risk-pool model. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs including the creation of a national risk-pool model. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs including the creation of a national risk-pool model. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs including the creation of a national risk-pool model. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs including the creation of a national risk-pool model. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs including the creation of a national risk-pool model. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs including the creation of a national risk-pool model. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs including the creation of a national risk-pool model. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics; prescription drug costs; risk adjustment; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics; prescription drug costs; risk adjustment; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics; prescription drug costs; risk adjustment; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics; prescription drug costs; risk adjustment; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics; prescription drug costs; risk adjustment; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics; prescription drug costs; risk adjustment; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics; prescription drug costs; risk adjustment; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics; prescription drug costs; risk adjustment; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.